A carregar...
Development of [(89)Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma
PURPOSE. Multiple myeloma (MM) is a bone marrow malignancy that remains mostly incurable. Elotuzumab is an FDA-approved therapeutic monoclonal antibody targeted to the cell surface glycoprotein CS1, which is overexpressed in MM cells. Identifying patients who will respond to CS1 targeted treatments...
Na minha lista:
| Publicado no: | Eur J Nucl Med Mol Imaging |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8110592/ https://ncbi.nlm.nih.gov/pubmed/33179150 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-020-05097-y |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|